See more : Osiris Acquisition Corp. (OSI) Income Statement Analysis – Financial Results
Complete financial analysis of OrganiGram Holdings Inc. (OGI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OrganiGram Holdings Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Jiin Ming Industry Co., Ltd. (3230.TWO) Income Statement Analysis – Financial Results
- Investeringsforeningen Bankinvest Globale Aktier Akk A Fund (BAIGAA.CO) Income Statement Analysis – Financial Results
- Yamaha Corporation (YAMCF) Income Statement Analysis – Financial Results
- Vornado Realty Trust (VNO) Income Statement Analysis – Financial Results
- Andhra Paper Limited (ANDHRAPAP.NS) Income Statement Analysis – Financial Results
OrganiGram Holdings Inc. (OGI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.organigram.ca
About OrganiGram Holdings Inc.
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 159.84M | 149.21M | 145.81M | 79.16M | 86.80M | 80.41M | 12.43M | 5.71M | 6.13M | 986.68K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.32M | 114.13M | 114.24M | 107.56M | 143.29M | 31.94M | 39.20M | 8.84M | 813.38K | 339.51K | 274.91K | 0.00 | 0.00 |
| Gross Profit | 47.52M | 35.07M | 31.57M | -28.40M | -56.49M | 48.47M | -26.78M | -3.13M | 5.31M | 647.17K | -274.91K | 0.00 | 0.00 |
| Gross Profit Ratio | 29.73% | 23.51% | 21.65% | -35.87% | -65.08% | 60.28% | -215.42% | -54.73% | 86.73% | 65.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.20M | 12.19M | 5.96M | 3.45M | 1.27M | 409.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 48.29M | 48.95M | 42.35M | 30.72M | 29.94M | 26.67M | 9.27M | 4.78M | 2.31M | 1.76M | 66.77K | 318.91K | 140.16K |
| Selling & Marketing | 19.85M | 17.86M | 16.86M | 15.81M | 16.53M | 14.63M | 6.30M | 2.85M | 1.76M | 720.97K | 181.44K | 0.00 | 0.00 |
| SG&A | 68.14M | 71.68M | 59.21M | 46.52M | 46.47M | 41.30M | 15.57M | 7.62M | 4.07M | 2.49M | 66.77K | 318.91K | 140.16K |
| Other Expenses | 3.85M | 0.00 | 5.15M | -5.53M | -6.37M | 664.00K | 509.00K | 416.36K | 0.00 | 0.00 | 0.00 | 56.33K | 0.00 |
| Operating Expenses | 83.20M | 271.48M | 70.32M | 44.44M | 41.37M | 42.37M | 16.08M | 8.04M | 4.07M | 2.49M | 66.77K | 375.25K | 140.16K |
| Cost & Expenses | 195.51M | 385.61M | 184.56M | 152.00M | 184.65M | 74.31M | -23.99M | 16.88M | 4.88M | 2.15M | 66.77K | 375.25K | 140.16K |
| Interest Income | 0.00 | 3.69M | 1.49M | 854.00K | 308.00K | 662.00K | 0.00 | 9.87K | 0.00 | 0.00 | 996.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 277.85K | 429.00K | 2.96M | 6.01M | 9.67M | 10.09M | 273.87K | 436.37K | 115.41K | 996.00 | 0.00 | -140.16K |
| Depreciation & Amortization | 12.08M | 23.42M | 24.91M | 31.03M | 17.96M | 8.90M | 3.53M | 1.56M | 785.59K | 414.80K | 173.53K | 0.00 | 0.00 |
| EBITDA | -23.59M | -25.37M | -15.21M | -42.92M | -122.66M | 12.70M | 41.40M | -9.62M | 2.03M | -746.65K | 106.76K | -375.25K | -140.16K |
| EBITDA Ratio | -14.76% | -17.00% | -10.43% | -54.22% | -93.42% | 17.09% | 321.38% | -168.30% | 33.15% | -75.42% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.67M | -48.79M | -38.75M | -91.82M | -145.51M | 5.49M | 36.42M | -11.17M | 1.25M | -1.16M | -66.77K | -375.25K | -140.16K |
| Operating Income Ratio | -22.32% | -32.70% | -26.58% | -115.99% | -167.65% | 6.82% | 292.99% | -195.44% | 20.33% | -117.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.77M | -184.21M | 24.38M | -38.88M | -46.98M | -11.36M | -8.64M | 211.32K | -398.97K | -117.90K | 1.38M | 0.00 | 0.00 |
| Income Before Tax | -45.44M | -233.00M | -14.37M | -130.70M | -146.63M | -5.88M | 27.78M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | 0.00 |
| Income Before Tax Ratio | -28.43% | -156.16% | -9.86% | -165.11% | -168.94% | -7.31% | 223.49% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.52M | -88.00K | 1.84M | -10.47M | 3.63M | 5.65M | -550.94K | -37.41K | 2.49K | 171.54K | 0.00 | 140.16K |
| Net Income | -45.44M | -229.48M | -14.28M | -132.55M | -136.16M | -9.50M | 20.51M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | -140.16K |
| Net Income Ratio | -28.43% | -153.80% | -9.80% | -167.43% | -156.87% | -11.82% | 165.04% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| EPS | -0.44 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.68 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| EPS Diluted | -0.42 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.65 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| Weighted Avg Shares Out | 103.80M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 30.14M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
| Weighted Avg Shares Out (Dil) | 108.38M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 31.72M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
Organigram Receives Health Canada's Final Redetermination on Jolts
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announced today that, despite strong evidence supporting its classification as an ingestible extract, it has received a final redetermination from Health Canada that its patented Edison Jolts lozenge...
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5
You get what you pay for and that includes stocks under $5. Yeah, I might be starting off on a negative foot but here's the deal: most securities that are priced this low are that way for a reason.
Top Marijuana Stocks For Trading Today 2024
More publicly traded cannabis companies are starting to report earnings. This alone has been another reason shareholders have seen a slight increase in trading momentum for marijuana stocks. Speculation is high in 2024 for those who are invested in legal...
2 Top Marijuana Penny Stocks with High Momentum Before March 2024
As March 2024 begins, marijuana stocks are catching the eyes of investors looking for potential growth opportunities. The cannabis industry in the U.S. has seen rapid expansion and evolution, driven by increasing legalization and public acceptance. Several marijuana companies, operating...
Organigram Applauds the Standing Committee on Finance's Recommendation on Excise Duty
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) enthusiastically supports the Standing Committee on Finance's recent recommendation on the Excise Duty framework. In a recently released report, titled ‘Shaping our Economic Future: Canadian Priorities,' the House...
Organigram and Aurora Cannabis increasingly attractive as Canopy Growth's core operations struggle: analysts
Cannabis firms OrganiGram Holdings (TSX-V:OGI, NASDAQ:OGI) and Aurora Cannabis Inc (TSX:ACB, NASDAQ:ACB) are increasingly attractive on the back of encouraging quarterly financial results, analysts at Jefferies believe. They have a ‘Buy' rating on Organigram, which they said remains a top...
3 Millionaire-Maker Cannabis Penny Stocks to Buy in February 2024
Support for the legalization of cannabis is at an all-time high. In fact, according to a recent Gallup poll, about 70% of all Americans support legalization.
Organigram Holdings Inc. (OGI) Q1 2024 Earnings Call Transcript
Organigram Holdings Inc. (OGI) Q1 2024 Earnings Call Transcript
Organigram Reports First Quarter Fiscal 2024 Results
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended December 31, 2023 (“Q1 Fiscal 2024”). “We certainly kicked off fiscal 2024 with a...
Leading Canadian Cannabis Stock Powers Through with Strong Weekly Momentum
In February 2024, top Canadian cannabis stocks showed mixed performance amid evolving market dynamics. Companies like Canopy Growth, Aurora Cannabis, and Tilray Brands remained focal points for investors. Market movements were influenced by quarterly earnings reports, with some companies exceeding...
Source: https://incomestatements.info
Category: Stock Reports